HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (Nasdaq: PIII), a patient- centered and physician-led population health management company (the “Company”), today announced that it has entered into definitive agreements to sell securities in a private placement with certain institutional investors.

内华达州亨德森（商业新闻短讯）--P3 Health Partners Inc.（纳斯达克：PIII），一家以患者为中心，医生为主导的人口健康管理公司（以下简称“公司”）今天宣布，它已经与某些机构投资者签订了以私募方式出售证券的最终协议。

The lead institutional investors in the private placement are affiliates of Chicago Pacific Founders (“CPF”). The transaction is expected to result in gross proceeds of approximately $42.2 million, including approximately $20.0 million of gross proceeds from purchases by affiliates of CPF, before deducting placement agent fees and offering expenses..

私募的主要机构投资者是芝加哥太平洋创始人（“CPF”）的附属公司。该交易预计将产生约4220万美元的总收益，其中包括CPF附属公司购买的约2000万美元总收益，然后再扣除配售代理费和发行费用。。

The Company plans to use the net proceeds from the financing for working capital and other general corporate purposes.

公司计划将融资净收益用于营运资本和其他一般公司用途。

Pursuant to the terms of the securities purchase agreements, the Company will issue approximately 67.4 million units at a price of approximately $0.6270 per unit, the “Minimum Price” as defined in the rules of the Nasdaq Stock Market LLC. Each unit consists of one share of Class A common stock and a warrant to purchase one share of Class A common stock at an exercise price of $0.5020.

根据证券购买协议的条款，公司将发行约6740万股股票，价格约为每股0.6270美元，这是纳斯达克股票市场有限责任公司规则中定义的“最低价格”。每股股票由一股a类普通股和一份以0.5020美元的行权价购买一股a类普通股的认股权证组成。

Certain institutional investors have elected to receive pre-funded warrants to purchase Class A common stock in lieu of a portion of their Class A common stock. The closing of the private placement is subject to certain conditions and is expected to occur on or about May 24, 2024..

某些机构投资者选择接受预先出资的认股权证来购买A类普通股，以代替其部分A类普通股。私募配售的结束取决于某些条件，预计将于2024年5月24日左右完成。。

William Blair & Company, L.L.C. acted as sole placement agent in connection with the financing.

William Blair&Company，L.L.C.担任融资的独家配售代理。

The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws. The securities being issued in the private placement may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws..

上述证券的发售是在不涉及公开发售的交易中进行的，并且这些证券尚未根据经修订的《1933年证券法》（“证券法”）或适用的州证券法进行登记。私募发行的证券不得在美国发售或出售，除非根据有效的注册声明或《证券法》和适用的州证券法的注册要求的适用豁免。。

This press release shall not constitute an offer to sell or a solicitation of an offer to buy the foregoing securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction..

本新闻稿不构成出售或招揽购买上述证券的要约，也不构成在根据任何州或其他司法管辖区的证券法进行注册或资格认证之前，在任何州或其他司法管辖区出售这些证券都是非法的。。

About P3 Health Partners (NASDAQ: PIII):

关于P3 Health Partners（纳斯达克股票代码：PIII）：

P3 Health Partners Inc. is a leading population health management company committed to transforming healthcare by improving the lives of both patients and providers. Founded and led by physicians, P3 has an expansive network of more than 2,900 affiliated primary care providers across the country. Our local teams of health care professionals manage the care of thousands of patients in 27 counties across five states.

P3 Health Partners Inc.是一家领先的人口健康管理公司，致力于通过改善患者和提供者的生活来改变医疗保健。P3由医生创建和领导，拥有全国2900多家附属初级保健提供者的庞大网络。我们当地的医疗保健专业团队管理着五个州27个县数千名患者的护理。

P3 supports primary care providers with value-based care coordination and administrative services that improve patient outcomes and lower costs. Through partnerships with these local providers, the P3 care team creates an enhanced patient experience by navigating, coordinating, and integrating the patient’s care within the healthcare system.

P3通过基于价值的护理协调和管理服务支持初级保健提供者，以改善患者的预后并降低成本。通过与这些当地提供者的合作，P3护理团队通过在医疗保健系统中导航、协调和整合患者的护理，创造了增强的患者体验。

For more information, visit www.p3hp.org and follow us on LinkedIn and Facebook.com/p3healthpartners..

有关更多信息，请访问www.p3hp.org，并在LinkedIn和Facebook.com/p3healthpartners上关注我们。。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. Words such as “anticipate,” “believe,” “budget,” “contemplate,” “continue,” “could,” “envision,” “estimate,” “expect,” “guidance,” “indicate,” “intend,” “may,” “might,” “plan,” “possibly,” “potential,” “predict,” “probably,” “pro-forma,” “project,” “seek,” “should,” “target,” or “will,” or the negative or other variations thereof, and similar words or phrases or comparable terminology, are intended to identify forward-looking statements.

本新闻稿包含《证券法》第27A节、经修订的《1934年证券交易法》第21E节和经修订的《1995年私人证券诉讼改革法》所指的前瞻性声明。诸如“预期”、“相信”、“预算”、“沉思”、“继续”、“可能”、“设想”、“估计”、“预期”、“指导”、“表明”、“打算”、“可能”、“可能”、“计划”、“可能”、“潜在”、“预测”、“可能”、“形式上”、“项目”、“寻求”、“应该”、“目标”或“意志”或其负面或其他变体，以及类似的单词或短语或类似的术语，旨在识别前瞻性陈述。

These forward-looking statements address various matters, including statements regarding the closing of the private placement, which reflect the Company’s expectations based upon currently available information and data..

这些前瞻性声明涉及各种事项，包括关于私募结束的声明，这些声明反映了公司基于当前可用信息和数据的期望。。

Because such statements are based on expectations as to future financial and operating results and are not statements of fact, actual results may differ materially from those projected or estimated and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements..

由于这些报表是基于对未来财务和经营成果的预期，而不是事实报表，因此实际结果可能与预测或估计结果存在重大差异，因此请注意不要过度依赖这些前瞻性报表。这些前瞻性陈述并不能保证未来的业绩、条件或结果，涉及许多已知和未知的风险、不确定性、假设和其他重要因素，其中许多因素不在公司的控制范围内，可能导致实际结果或结果与前瞻性陈述中讨论的结果有重大差异。。

Important risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in forward-looking statements include, among others, changes in market or industry conditions, regulatory environment, competitive conditions, and receptivity to our services; our ability to continue our growth and expand our operations; changes in laws and regulations applicable to our business; our ability to maintain our relationships with health plans and other key payers; increased labor costs; our ability to recruit and retain qualified team members and independent physicians; and other factors discussed in Part I, Item 1A.

可能导致我们的实际业绩和财务状况与前瞻性报表中所示存在重大差异的重要风险和不确定性包括市场或行业状况、监管环境、竞争状况以及对我们服务的接受程度的变化；我们继续增长和扩大业务的能力；适用于我们业务的法律法规的变更；我们维持与健康计划和其他关键付款人关系的能力；劳动力成本增加；我们招募和留住合格团队成员和独立医生的能力；以及第一部分第1A项中讨论的其他因素。

“Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (the “SEC”) on March 28, 2024, and in the Company’s other filings with the SEC. All information in this press release is as of the date hereof, and the Company undertakes no duty to update or revise this information unless required by law.

公司于2024年3月28日向美国证券交易委员会（“SEC”）提交的截至2023年12月31日的年度报告表10-K中的“风险因素”，以及公司向SEC提交的其他文件中的“风险因素”。本新闻稿中的所有信息均截至本新闻稿日期，除非法律要求，否则公司不承担更新或修改此信息的义务。

You are cautioned not to place undue reliance on any forward-looking statements contained in this press release..

提醒您不要过度依赖本新闻稿中包含的任何前瞻性声明。。